Domperin

Quick links to important sections

Domperin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Domperin

What is Domperin?

Domperin is a pharmacological agent primarily classified as a dopamine antagonist. It is used to manage symptoms associated with gastrointestinal motility disorders and to alleviate nausea and vomiting.

Mechanism of Action

The active ingredient in Domperin works by blocking dopamine receptors located in the upper digestive tract and the chemoreceptor trigger zone. By inhibiting dopamine's inhibitory effects on the muscles of the stomach and small intestine, the medication helps to:

  • Increase the tone of the lower esophageal sphincter.
  • Enhance gastroduodenal coordination.
  • Facilitate gastric emptying by promoting peristaltic contractions.

Unlike some earlier dopamine antagonists, Domperin does not readily cross the blood-brain barrier in significant amounts, which limits its impact on the central nervous system while maintaining its effectiveness on the digestive system and the area of the brain responsible for the vomiting reflex.

Therapeutic Intent

The primary purpose of this medication is to restore the natural rhythm of the digestive system. It is commonly utilized for the relief of symptoms such as:

  • Epigastric a sensation of fullness.
  • Upper abdominal bloating.
  • Nausea and vomiting induced by various factors, including the use of other medications.

What side effects are possible with Domperin?

Possible Side Effects and Safety Information

Domperidone's official safety profile, as classified by regulatory agencies, is dominated by concerns regarding the cardiovascular system, alongside more frequent effects observed in the gastrointestinal and endocrine systems. Adverse reactions are systematically grouped by affected body system and estimated frequency.


Frequency-Classified Adverse Reactions

Classification Representative Adverse Reactions
Common (ge 1/100) Dry mouth
Uncommon (ge 1/1000) Headache, somnolence (drowsiness), anxiety, asthenia (weakness), diarrhea, rash, prolactin-related effects (e.g., breast pain, decreased male libido)
Frequency Not Known Ventricular arrhythmias (QTc prolongation, Torsade de Pointes), sudden cardiac death, agitation, extrapyramidal disorders, anaphylactic reactions, urinary retention, gynecomastia, menstrual irregularities

Serious Safety Concerns and Restrictions

Official labeling emphasizes the risk of serious ventricular arrhythmias and sudden cardiac death. The risk is documented as higher in patients over 60 years old, with daily doses greater than 30 mg, and with longer treatment periods.

The medicine is contraindicated by regulatory authorities for use in patients with pre-existing QTc prolongation, significant electrolyte disturbances, congestive heart failure, or moderate to severe hepatic impairment. Extrapyramidal disorders (uncontrolled movements) are explicitly noted as being more likely to happen in children.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Domperidone primarily by its potential to cause serious cardiovascular toxicity and Central Nervous System (CNS) manifestations. Overdose has been reported following the ingestion of high doses, and is noted in official labeling to occur primarily in infants and children.

Overdose manifestations that have been documented include disorientation, somnolence (drowsiness), agitation, convulsions (seizures), and altered consciousness. The most prominent severe clinical signs relate to cardiac effects, including QT interval prolongation, serious ventricular arrhythmias, and the risk of sudden cardiac death.

Category Official Regulatory Statement
Life-Threatening Risk Serious ventricular arrhythmias and sudden cardiac death.
Emergency Action Seek immediate medical attention or contact emergency services straight away.
Trigger for Help Stop taking the drug immediately if signs of cardiac arrhythmia occur (e.g., fainting, irregular heartbeat).
Management Note No specific antidote is known; treatment is limited to symptomatic and supportive therapy.

ECG monitoring must be carried out due to the possibility of serious heart rhythm changes. For CNS manifestations, such as extrapyramidal reactions, anticholinergic or anti-Parkinson medicines may be useful as part of supportive care, as noted in the regulatory documents.

Therapeutic Uses of Domperin

Quick Facts about Domperin

  • Relief of symptoms: May assist in the relief of symptoms associated with nausea.
  • Vomiting management: Used in the management of vomiting.

What Domperin Treats: Main Uses and Benefits

Domperin is a treatment option used in the management of symptoms associated with nausea and vomiting.

The therapeutic profile of Domperin is supported by its action as an antiemetic agent. It is intended for short-term use at the lowest effective dose.

In some regions, the medicine is also used to manage symptoms related to certain gastrointestinal issues, such as epigastric fullness, abdominal discomfort, and early satiety, though data supporting its effectiveness for indications other than nausea and vomiting may be limited in some contexts. Furthermore, some patients with severe gastrointestinal motility disorders may receive treatment with Domperin through special access programs.

Regulatory References

  1. EMA therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Domperin? (Official Regulatory Information)

Official labeling defines Domperin (Domperidone) eligibility through strict contraindications and age-weight restrictions, primarily due to cardiac risk.

Eligibility and Non-Eligibility

Classification Status According to Regulatory Documents
Eligible Population Adults and adolescents 12 years of age weighing 35 kg (for the licensed indication).
Absolute Contraindication Patients with moderate or severe hepatic impairment (Child-Pugh 7); those with existing QTc prolongation, underlying cardiac diseases (e.g., congestive heart failure), or significant electrolyte disturbances.
Restricted Use Severe renal impairment requires reduction of dosing frequency and regular patient review. Use in older adults (> 60 years) requires caution due to higher cardiac risk.
Pregnancy and Lactation Pregnancy: Use should only be considered when justified by the anticipated therapeutic benefit. Lactation: Use is not recommended due to excretion in human milk and potential cardiac risk to the infant.

Prohibited Co-administration

The medicine is strictly contraindicated when co-administered with QT-prolonging medicinal products or potent CYP3A4 inhibitors.

Pediatric Limitations

Domperin is not recommended for children < 12 years of age or adolescents weighing < 35 kg, as efficacy has not been established and licensing has been restricted in this population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Domperin (Domperidone) is strictly regulated, primarily focusing on managing the risk of serious cardiac events. Regulatory authorities mandate formal restrictions based on the drug's metabolism and potential for QTc interval prolongation.


Contraindicated Combinations

Co-administration with the following drug classes is formally prohibited (contraindicated) due to the heightened risk of adverse cardiac effects:

  • Potent CYP3A4 Inhibitors: These agents significantly reduce Domperidone's clearance, leading to high plasma concentrations. Examples include certain azole antifungals (e.g., Ketoconazole) and macrolide antibiotics (e.g., Erythromycin).
  • QTc-Prolonging Medicinal Products: Combining Domperidone with any medicine known to prolong the QTc interval creates an additive pharmacodynamic risk. Examples include certain antiarrhythmics and antipsychotics.

Documented Pharmacokinetic and Administration Interactions

  • Moderate CYP3A4 Inhibitors (e.g., Diltiazem) also increase Domperidone exposure, requiring caution.
  • Antisecretory Agents (like antacids or proton pump inhibitors) reduce the oral bioavailability of Domperidone; therefore, the administration of these agents must be separated in time.
  • Domperin is contraindicated in patients with moderate or severe hepatic impairment, as their reduced liver function amplifies the systemic exposure and interaction risk.

Mechanism of Action

Influence on Upper Gastrointestinal Motility

This drug acts as an antagonist (blocker) on Dopamine D2 receptors found in the muscle and nerve layers of the stomach and small intestine. By blocking dopamine's inhibitory effect, the drug permits the release of the neurotransmitter acetylcholine, which increases the strength and frequency of muscle contractions (peristalsis). This action consequently increases the speed of content transit through the upper digestive system.


D2 Receptor Antagonism in the Chemoreceptor Trigger Zone

A key part of the mechanism involves the selective blockade of D2 receptors in the Chemoreceptor Trigger Zone (CTZ), a region outside the main blood-brain barrier that detects circulating chemical signals. This targeted antagonism reduces the responsiveness of the CTZ to these signals, consequently disrupting the signaling sequence to the emetic center.


Effect on Prolactin Secretion via the Pituitary Gland

The drug's mechanism also extends to the pituitary gland, where it blocks D2 receptors that normally regulate the hormone prolactin. Because dopamine naturally inhibits prolactin release, blocking its receptor results in an elevation of prolactin concentration in the bloodstream, a direct physiological result of the drug’s D2 receptor mechanism.

Dosage and Administration Information

How to Use Domperin: Administration Guidelines

Domperin is an orally administered medicine that must be taken strictly according to the dose and duration limits established for its use. It is recommended to use the lowest effective dose for the shortest possible duration, with treatment generally not exceeding one week.

Dosing and Timing

The standard route of administration is oral (e.g., tablets or oral suspension). The drug is intended to be taken before meals for optimal drug absorption; absorption is delayed if taken after food.

Patient Group Dose Per Administration Maximum Daily Dose Dosing Frequency
Adults and Adolescents (ge 12 years, ge 35 kg) 10 mg 30 mg Up to three times per day

Special Use Conditions

For patients with severe renal impairment (kidney issues), the dosing frequency must be reduced to once or twice daily, depending on the degree of impairment, due to prolonged elimination of the drug. Such patients should be regularly reviewed.

Missed Dose Instructions

If a scheduled dose is missed, the patient should omit the forgotten dose and resume the usual dosing schedule. The dose must not be doubled to compensate for the missed administration.

These instructions define the standardized, fixed-schedule protocol for administering Domperin, specifying the maximum daily intake and the critical limit on treatment length.

Recent Clinical Evidence

Domperin: Recent Clinical Evidence

Evidence for Use in Nausea and Vomiting (Adults and Adolescents)

This section summarizes the structure of short-term randomized controlled trials and meta-analyses that evaluated Domperin in studies examining patient-reported experiences related to nausea and vomiting symptoms in adults and adolescents. Research explored how symptoms change over time in these populations, monitoring perceived discomfort and changes in symptom scores over periods as brief as 48 hours up to one week. The collected evidence describes patterns observed in the studies regarding symptom measurements following short-term administration. However, research highlights that follow-up durations were limited, meaning there is limited information for long-term outcomes and the evolution of symptom patterns over extended periods.


Evidence for Gastrointestinal Motility Disorders

This section outlines clinical studies that examined Domperin in studies exploring how symptoms change over time in conditions characterized by fluctuating or unstable manifestations, such as chronic dyspepsia and gastroparesis. While the studies report how symptoms evolved in the observed populations, the findings were mixed across various studies, especially concerning objective physiological measures. Evidence derived from settings with varying symptom burdens show patterns related to inconsistency. The available data for the long-term use for these specific GI motility disorders was described as extremely limited by regulatory reviews.


Research Findings in the Pediatric Population

This section details the findings from the randomized, placebo-controlled studies specifically conducted in children with acute gastroenteritis. Research examined Domperin in studies focusing on episodes where symptoms become more noticeable in children younger than 12 years. The evidence describes how patient-reported outcomes capturing phases of heightened symptom activity (such as the frequency of vomiting) did not describe a significant difference when compared to the placebo control group. This lack of measured outcomes led to the drug's use being removed from product information in several major regulatory regions.


Evidence Gaps and Areas of Uncertainty

This final section synthesizes the limitations noted by regulatory bodies and scientific reviews. The evidence is limited and heterogeneous for indications other than acute nausea and vomiting. Evidence that involves directly comparing Domperin against other therapeutic options remains insufficient in some research areas. Furthermore, regulatory reviews describe that the overall body of work has limited information to comprehensively address long-term outcomes and the potential for symptom rebound or tolerance over extended treatment periods.

Key Studies & References

  1. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis

Frequently Asked Questions (FAQ)

Common questions about Domperin (FAQ)

Q: Is Domperin the same as medications like Metoclopramide or only similar?

A: Domperin (Domperidone) and Metoclopramide are both classified as dopamine receptor antagonists. However, official drug information describes Domperin as having a predominantly peripheral action, meaning it acts mainly outside the central nervous system. This pharmacological distinction is often cited in regulatory discussions regarding the potential for central nervous system-related side effects.

Q: How quickly does Domperin start working for nausea?

A: According to official product information, the anti-nausea effect is typically noticeable within 30 to 60 minutes after taking the oral dose. Regulatory documents state that absorption may be significantly delayed if the medicine is taken after a meal. This is why the product information recommends taking it before food.

Q: Does Domperin cause drowsiness or fatigue?

A: Official product information lists both somnolence (drowsiness) and asthenia (weakness or a lack of energy, which is related to fatigue) as uncommon side effects. This means that while they are not frequently reported, some people may experience them.

Q: Can Domperin be taken with common over-the-counter pain relievers?

A: Regulatory documents primarily restrict combining Domperin with specific drug classes, mainly those that affect heart rhythm or are potent CYP3A4 inhibitors. There is generally no explicit contraindication for common non-prescription pain relievers. Any decision regarding combining Domperin with other medications should be made in consultation with a healthcare professional to assess potential interaction risks.

Q: Can children be given Domperin, and is the dosage different?

A: Domperin is not recommended for children under 12 years of age or those weighing less than 35 kg. This restriction is based on safety concerns, including a potential higher risk of uncontrolled movements (extrapyramidal disorders), as efficacy has not been established and licensing has been restricted in this population.

Q: Does taking Domperin affect your heart rate?

A: Official warnings emphasize a risk of serious effects on the heart's electrical system, including ventricular arrhythmias and QTc prolongation. These issues involve the heart's rhythm, which can sometimes result in an irregular or fast heartbeat. The product is contraindicated for people with pre-existing heart rhythm issues or other cardiac diseases.

Q: What research supports the use of Domperin for digestive motility?

A: Domperin's mechanism of action involves blocking dopamine D2 receptors to help increase the speed and strength of muscle contractions in the upper digestive system. Clinical studies have examined Domperin's role in improving the movement of food through the stomach in certain conditions, such as gastroparesis, consistent with its mechanism of action.

Q: Does alcohol change how Domperin works in the body?

A: Official health guidance advises users to avoid or limit alcohol consumption while taking Domperin. Alcohol may potentially increase the risk of certain side effects, such as increasing feelings of drowsiness or affecting the heart's electrical rhythm.

Q: Can people with lactose intolerance take all forms of Domperin?

A: The inactive ingredients (excipients) for Domperin tablets often include lactose. Individuals with severe lactose intolerance are advised to review the specific inactive ingredients for the oral tablet formulation with a healthcare provider.

Q: Does Domperin help with a feeling of fullness or just nausea?

A: Yes, Domperin is officially used to alleviate symptoms associated with slow stomach emptying, which includes a persistent feeling of fullness (early satiety), in addition to nausea and vomiting.

Q: Are there any common side effects people report when first starting Domperin?

A: The most common side effect reported in clinical trials and regulatory documents is dry mouth. Other effects that are less common but still may occur include headache, drowsiness, and diarrhea.

Q: Is it normal to feel a dry mouth while taking Domperin?

A: Yes, dry mouth is listed as a Common side effect in the drug's official product information. This means it is among the more frequently reported effects experienced by people taking Domperin.

Q: Is Domperin safe to use for a long period of time?

A: Official regulatory guidance strongly advises using Domperin at the lowest effective dose for the shortest possible duration, generally not exceeding one week. Long-term use or high doses are associated with a greater and more serious risk of cardiac side effects.

Q: Are there any known withdrawal symptoms if I stop taking Domperin suddenly?

A: While not listed as common or uncommon side effects in the official product monograph, post-marketing safety reports have included descriptions of symptoms experienced upon stopping the drug. These have included symptoms such as anxiety, insomnia, or depression, particularly after prolonged use.

Q: Does Domperin affect liver function tests?

A: Domperin is metabolized by the liver and is contraindicated (strictly prohibited) for patients with moderate or severe liver impairment. This restriction is based on concerns that reduced liver function could lead to increased levels of the drug in the body, and monitoring of liver function is often considered in clinical practice.

Q: Can Domperin be crushed or split if it's a tablet?

A: Generally, the tablets are advised to be swallowed whole with water. Specific advice on modifying the tablet form should only be followed if provided directly by a healthcare professional.

Q: Why do some people take Domperin for migraine-related nausea?

A: Domperin is an anti-emetic approved for the relief of nausea and vomiting. This anti-emetic action is utilized in clinical settings when treating symptoms of severe nausea that accompany a migraine episode, though this specific use is generally considered off-label.

Q: Are there any warnings about driving while on Domperin?

A: Because side effects like dizziness and somnolence (drowsiness) have been reported, official product information advises caution. Patients are advised to assess their reaction to the medicine and refrain from driving or operating machinery if they experience these effects.

Q: Can Domperin make existing anxiety worse?

A: Anxiety is listed as an uncommon side effect in the official safety profile. Furthermore, some safety reports have indicated that anxiety symptoms may also be a component of the withdrawal syndrome if the medication is stopped abruptly.

Q: Does Domperin interact with herbal supplements like St. John's Wort?

A: Regulatory documents prohibit combining Domperin with strong inhibitors of the CYP3A4 enzyme. St. John's Wort has complex interactions with the CYP3A4 system, and any decision regarding combining Domperin with this supplement should involve a consultation with a healthcare professional due to the potential for metabolic interaction.

Q: What is the maximum duration of treatment with Domperin that is generally recommended?

A: Official regulatory guidance strictly recommends that treatment duration be the shortest necessary time, which typically means not exceeding one week. This caution is in place to minimize the risk of serious cardiac side effects.

Q: Why is Domperin sometimes restricted or harder to get in certain countries?

A: Major regulatory agencies worldwide have placed significant restrictions on the drug's use, dosage, and duration due to the documented increased risk of serious cardiac adverse events. These restrictions aim to ensure that the drug is used only when the benefits outweigh these specific risks.

Q: Is Domperin considered an antiemetic or a prokinetic drug?

A: It is officially classified as both a gastroprokinetic agent and a dopamine receptor antagonist. Functionally, it acts as an antiemetic to relieve nausea and vomiting and a prokinetic to stimulate gastrointestinal movement.

Q: Does Domperin have any effect on blood sugar levels?

A: Domperin is sometimes used to treat stomach emptying issues in people with diabetes. While not directly indicated as a blood sugar medication, some studies in this population have investigated its indirect impact on the control of blood glucose levels through improved gastric emptying.

Q: Why is Domperin not the first-line treatment for all types of nausea?

A: Because of the required safety precautions and the potential for cardiac risk, regulatory authorities mandate that the drug be used only for the shortest time and at the lowest dose. This safety profile generally reserves its use for nausea and vomiting that is not effectively managed by other treatments.

Q: What is the half-life of Domperin in the body?

A: The official product monograph states that the average elimination half-life in healthy adults is generally between 7 to 9 hours. This is the time it takes for the concentration of the drug in the body to be reduced by half. The half-life may be significantly longer in patients with severe kidney problems.

Q: Are there different strengths of Domperin available?

A: Yes, Domperin is commonly available in various forms, typically including 10 mg tablets and an oral suspension (often 1 mg/ mL). Other forms, such as suppositories, may also be available in some regions.

Q: Does Domperin affect the absorption of other oral medications?

A: Yes, because Domperin increases the speed of content movement through the stomach, it may influence the rate or extent of absorption of other oral medicines taken at the same time. This is why separation of administration time is often required for concurrent treatments.

Q: Are there specific symptoms that mean I should stop taking Domperin immediately?

A: Yes, regulatory authorities advise that treatment must be stopped immediately if a patient experiences signs or symptoms that may be associated with a cardiac arrhythmia. These critical symptoms include palpitations, fainting, or severe dizziness.

How should Domperin be stored and disposed of?

How to Store and Dispose of Domperidone

Storage and handling of Domperidone (Domperin) must strictly follow the conditions defined in the official regulatory labeling to ensure product stability and safety.

Storage Requirements

Domperidone is required to be stored at room temperature, typically 20 °C to 25 °C (68 °F to 77 °F), and must not be stored above 25 °C. The product must be protected from both light and moisture, and the container must be kept tightly closed and in its original packaging. For child-safety, the medicine must always be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Domperidone must be disposed of according to national and local regulations. The preferred method is using an official drug take-back program. If a take-back program is unavailable, follow the procedure of mixing the medicine with an undesirable substance (such as dirt or used coffee grounds), sealing it in a container, and discarding it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Domperin found in:

A-Z Index: